Noradrenergic mediation of experimental cerebrovascular spasm.
D000818:Animals; D001488:Basilar Artery / Q000294:innervation / Q000473:pathology; D001769:Blood / Q000378:metabolism; D001949:Bretylium Compounds / Q000494:pharmacology; D002395:Catecholamines / Q000032:analysis; D003714:Denervation; D005453:Fluorescence; D000882:Haplorhini; D006651:Histocytochemistry; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D009130:Muscle, Smooth / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism* / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011984:Sensory Receptor Cells / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D013345:Subarachnoid Hemorrhage / Q000150:complications; D014439:Tyramine / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000378:metabolism; D014711:Vertebral Artery
D001949:Bretylium Compounds; D002395:Catecholamines; D014662:Vasoconstrictor Agents; D010643:Phenoxybenzamine; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D009638:Norepinephrine; D014439:Tyramine